Allam Maha M, Abd El Moneim Elhamy, Hassouna Mouna M, El Jaky Ashraf, Zaghlah Hassan
Department of Clinical Pathology, National Liver Institute-Menoufiya University, Menoufiya, Egypt.
Egypt J Immunol. 2009;16(1):17-25.
CC chemokine receptors (CCR) have an important role in the recruitment of leukocytes to the site of inflammation. The migration and metastasis of tumor cells shares many similarities with leukocyte trafficking, which is mainly regulated by chemokine receptor-ligand interactions. CCR1 and CCR5 are highly expressed in hepatocellular carcinoma (HCC) cells and tissues with unknown functions. In this study, we estimated the surface expression of chemokine receptors CCR1 and CCR5 on the lymphocytes of peripheral blood from patients with HCC in an attempt to identify their roles in tumorigenesis. The study was conducted on 52 patients of which, 24 of them with confirmed HCC and 28 with chronic hepatitis C virus infection. In addition, 20 apparently healthy controls with matched age and sex were also included in the study. All patient and control groups were subjected to the following: thorough history taking, clinical examination, abdominal ultrasonography and fine needle liver biopsy for patient's group when needed, complete blood count, liver function tests, viral markers for hepatitis B and C, serum alpha fetoprotein and flowcytometric detection of chemokine receptors CCR1 and CCR5 on peripheral blood T lymphocytes. The expression of chemokine receptors CCR1 and CCR5 on CD4+ and CD8+ T lymphocytes was significantly less in HCC and hepatitis C patient groups as compared to control group. Moreover, a significant decrease in the levels of CCR1 and CCR5 on CD8+ T lymphocytes was detected in HCC patients compared to patients with chronic HCV; however, it was not statistically significant for CD4+ cells. Furthermore in HCC patients, levels of CCR1 and CCR5 were significantly less in patients with large tumor size than small sized tumor. Data obtained showing reduced surface expression of CCR1 and CCR5 on CD4 and CD8 T lymphocytes reflect their possible role in altering the host's immune defense and disease pathogenesis, thus may be helpful for therapy design to ameliorate disease progression.
CC趋化因子受体(CCR)在白细胞募集至炎症部位的过程中发挥着重要作用。肿瘤细胞的迁移和转移与白细胞运输有许多相似之处,而白细胞运输主要由趋化因子受体 - 配体相互作用调节。CCR1和CCR5在肝细胞癌(HCC)细胞和组织中高表达,但其功能尚不清楚。在本研究中,我们评估了HCC患者外周血淋巴细胞上趋化因子受体CCR1和CCR5的表面表达,以试图确定它们在肿瘤发生中的作用。该研究对52名患者进行,其中24名确诊为HCC,28名患有慢性丙型肝炎病毒感染。此外,20名年龄和性别匹配的明显健康对照也纳入了研究。所有患者和对照组均接受以下检查:详细病史采集、临床检查、腹部超声检查,必要时对患者组进行细针肝活检、全血细胞计数、肝功能检查、乙肝和丙肝病毒标志物检测、血清甲胎蛋白以及外周血T淋巴细胞上趋化因子受体CCR1和CCR5的流式细胞术检测。与对照组相比,HCC和丙肝患者组中CD4 +和CD8 + T淋巴细胞上趋化因子受体CCR1和CCR5的表达明显减少。此外,与慢性丙肝患者相比,HCC患者CD8 + T淋巴细胞上CCR1和CCR5水平显著降低;然而,CD4 +细胞的差异无统计学意义。此外,在HCC患者中,肿瘤体积大的患者CCR1和CCR5水平明显低于肿瘤体积小的患者。所获得的数据显示CD4和CD8 T淋巴细胞上CCR1和CCR5的表面表达降低,反映了它们在改变宿主免疫防御和疾病发病机制中的可能作用,因此可能有助于设计改善疾病进展的治疗方案。